ClinicalTrials.gg
CompletedNCT02104830Updated Oct 24, 2016Results posted

Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients

A Phase 3 interventional study of Empegfilrastim 6 mg and Filgrastim in Chemotherapy-induced Neutropenia, sponsored by Biocad. Completed at 13 sites in Russian Federation. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-10-24.

Sponsored by Biocad · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing filgrastim in Neutropenia — 1 open to participants now, 1 under way, none of them phase 3. Filgrastim · Neutropenia.

Enrollment
9th of 19
135 · median 130
Started
2013
with 1 other
Phase 3
6 of 21
none open now
Registered
15th of 21
by date
Lead sponsor
2 of 21
Biocad

Among the 21 studies testing filgrastim in Neutropenia, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 15th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

1 of the 21 studies testing filgrastim in Neutropenia is open now. Recruiting first, the newest first:

About filgrastim

Filgrastim: first FDA approval 1991 (NEUPOGEN), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing filgrastim in Neutropenia, or all of them as a file.
02

Study summary

The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastim and daily dosing of filgrastim for prevention of neutropenia in patients receiving AT (docetaxel 75 mg/m2 + doxorubicin 50 mg/m2).

Read the detailed description

BCD-017-3 is an double-blind randomized phase III clinical study to compare the incidence of CTCAE grade 3/4 neutropenia after a single administration of recombinant human pegylated filgrastim empegfilgrastim (Extimia®) at a dose of 6 or 7.5 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day for neutropenia prophylaxis in breast cancer patients receiving myelosuppressive chemotherapy.

The study also includes the following determination of pharmacokinetic parameters after repeated administration of the study drug.

03

Conditions studied

  • Chemotherapy-induced Neutropenia

Keywords

  • empegfilgrastim
  • pegylated filgrastim
  • neutropenia
  • febrile neutropenia
  • chemotherapy-associated neutropenia
  • breast cancer
  • docetaxel
  • doxorubicin
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form;
  • verified diagnosis of stage IIb/III/IV breast cancer;
  • Age of 18-70 years inclusive;
  • of at least 6 months after inclusion in the study;
  • If the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study;
  • Performance Status of 0- 2, not increasing within during 2 weeks before randomization;
  • ANC level of 1500/μL and more at the beginning of the study
  • count of 100 000/μL and more at the beginning of the study
  • level of 90 g/l and more
  • Creatinine level \<1.5 mg/dl
  • Total level \<1.5 × the (ULN)
  • and/or AST levels \<2.5×ULN (5×ULN for patients with liver );
  • Alkaline phosphatase \<5×ULN;
  • >50% and more;
  • If the patient had received and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin,if in this study planned 6 cycles of chemotherapy ;
  • If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 350 mg/m2 for doxorubicin or 660 mg/m2 for epirubicin,if in this study planned 4 cycles of chemotherapy ;
  • Ability of the participant to follow the protocol requirements, according to the Investigator's opinion;
  • Patients of must implement reliable measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug;
  • Patients should be able to follow the Protocol procedures (according to Investigator's assessment.

Exclusion criteria

Exclusion Criteria:

  • Patient has received two or more chemotherapy regimens for the breast cancer;
  • Documented to filgrastim, pegfilgrastim, docetaxel, doxorubicin, dexamethasone and/or its , PEGylated drugs, recombinant proteins.
  • Pregnancy or breastfeeding;
  • Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim administration;
  • Concomitant radiotherapy (except selective radiotherapy of bone metastases);
  • Surgery, radiotherapy (except selective radiotherapy of bone metastases), administration of any experimental drugs within 30 days prior randomization;
  • History of bone marrow/stem cell transplantation;
  • Conditions limiting the patient's ability to follow the protocol;
  • grade 3-4 neuropathy;
  • , , , T.Pallidum infection(s);
  • Acute or active chronic infections;
  • Severe concurrent diseases (for example, severe arterial hypertension, severe heart failure, and other);
  • Severe depression, schizophrenia, any other mental disorders;
  • Obstacles in intravenous administration of study drugs;
  • Simultaneous participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Empegfilgrastim 6 mg

    Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days

    Biological: Empegfilrastim 6 mg · Biological: Placebo №2

  • Experimental
    Empegfilgrastim 7.5 mg

    Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days

    Biological: Placebo №2 · Biological: Empegfilrastim 7.5 mg

  • Active comparator
    Filgrastim

    Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml subcutaneously, 24 h after the chemotherapy.

    Biological: Filgrastim · Biological: Placebo №1

Interventions

  • Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.

    Also known as: Extimia, metpegfilgrastim, pegylated filgrastim, peg-GCSF

  • BiologicalFilgrastim

    Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.

    Also known as: GCSF

  • BiologicalPlacebo №1

    Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.

  • BiologicalPlacebo №2

    Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.

  • Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.

    Also known as: Extimia, metpegfilgrastim, pegylated filgrastim, peg-GCSF

06

What researchers measure

Primary outcomes

  1. Duration of Neutropenia CTCAE Grade 4

    The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).

    Time frame: 3 weeks

Secondary outcomes

  1. The Duration of Grade 4 Neutropenia From the 2nd (Week 6) to 4th Cycle (Week 12);

    Time frame: 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)

  2. The Incidence of Severe Neutropenia (Grade 3-4)

    Time frame: 16 weeks

  3. Low Level (Nadir) ANC x 10^9/L

    Time frame: 1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)

  4. Neutropenia Duration, Any Grade

    Time frame: 1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)

  5. Duration From ANC Nadir to ANC < 2.0 x 10^9/L

    Time frame: 1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)

07

Results

Posted Oct 24, 2016

Participant flow

Participant flow — Overall Study
MilestoneEmpegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastim
Started424343
Completed383636
Not completed477

Outcome measures

PrimaryDuration of Neutropenia CTCAE Grade 4

The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).

Time frame:
3 weeks
Reported as:
Mean · days
Duration of Neutropenia CTCAE Grade 4
daysEmpegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastim
Duration of Neutropenia CTCAE Grade 40.905 ± 1.2060.791 ± 1.0131.725 ± 1.519
SecondaryThe Duration of Grade 4 Neutropenia From the 2nd (Week 6) to 4th Cycle (Week 12);
Time frame:
2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)
Reported as:
Mean · days
The Duration of Grade 4 Neutropenia From the 2nd (Week 6) to 4th Cycle (Week 12);
daysEmpegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastim
2nd cycle (week 6)0.452 ± 1.1940.326 ± 0.9190.925 ± 1.385
3rd cycle (week 9)0.244 ± 0.7340.310 ± 0.6800.641 ± 0.932
4th cycle (week 12)0.195 ± 0.6010.475 ± 1.3200.892 ± 1.197
SecondaryThe Incidence of Severe Neutropenia (Grade 3-4)
Time frame:
16 weeks
Reported as:
Number · participants
The Incidence of Severe Neutropenia (Grade 3-4)
participantsEmpegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastim
The Incidence of Severe Neutropenia (Grade 3-4)403440
SecondaryLow Level (Nadir) ANC x 10^9/L
Time frame:
1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)
Reported as:
Mean · cells x 10^9/L
Low Level (Nadir) ANC x 10^9/L
cells x 10^9/LEmpegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastim
1st cycle (week 3)0.68 ± 0.680.91 ± 1.110.47 ± 0.74
2nd cycle (week 6)1.44 ± 1.302.10 ± 1.780.87 ± 1.12
3rd cycle (week 9)1.77 ± 1.391.88 ± 1.710.94 ± 1.04
4th cycle (week 12)1.67 ± 1.122.07 ± 1.750.75 ± 0.87
SecondaryNeutropenia Duration, Any Grade
Time frame:
1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)
Reported as:
Mean · days
Neutropenia Duration, Any Grade
daysEmpegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastim
1st cycle (week 3)2.214 ± 1.1521.953 ± 1.1944.0 ± 3.121
2nd cycle (week 6)1.881 ± 2.2761.233 ± 1.7022.775 ± 2.434
3rd cycle (week 9)1.585 ± 1.8971.024 ± 1.1992.487 ± 2.480
4th cycle (week 12)1.146 ± 1.1951.525 ± 2.3642.919 ± 2.488
SecondaryDuration From ANC Nadir to ANC < 2.0 x 10^9/L
Time frame:
1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)
Reported as:
Mean · days
Duration From ANC Nadir to ANC < 2.0 x 10^9/L
daysEmpegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastim
1st cycle (week 3)1.74 ± 0.981.51 ± 0.862.98 ± 2.40
2nd cycle (week 6)1.43 ± 1.291.05 ± 1.312.05 ± 1.08
3rd cycle (week 9)1.20 ± 1.210.98 ± 0.901.90 ± 1.87
4th cycle (week 12)1.12 ± 1.051.03 ± 1.202.14 ± 1.70

Adverse events

Collected over 3 month. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empegfilgrastim 6 mg—1/42 (2.4%)42/42 (100%)
Empegfilgrastim 7.5 mg—1/43 (2.3%)43/43 (100%)
Filgrastim—5/43 (11.6%)43/43 (100%)
Most frequent serious events
Most frequent serious events
EventEmpegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastim
Uterine bleedingReproductive system and breast disorders1/420/430/43
Febrile neutropeniaBlood and lymphatic system disorders0/421/431/43
Left hand fractureMusculoskeletal and connective tissue disorders0/420/431/43
nose furunculus 3 gradeInfections and infestations0/420/431/43
PneumoniaRespiratory, thoracic and mediastinal disorders0/420/431/43
AgranulocytosisBlood and lymphatic system disorders0/420/431/43
Most frequent other events
Showing 10 of 15
Most frequent other events
EventEmpegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastim
neutropenia any gradeBlood and lymphatic system disorders41/4237/4341/43
LeucopeniaBlood and lymphatic system disorders41/4238/4341/43
Weakness / astheniaGeneral disorders26/4224/4324/43
AnemiaBlood and lymphatic system disorders17/4213/4319/43
HyperglycemiaEndocrine disorders6/428/439/43
HyperbilirubinemiaHepatobiliary disorders7/427/432/43
ArthralgiaMusculoskeletal and connective tissue disorders6/423/433/43
Liver enzymes (ALT) elevationHepatobiliary disorders4/422/432/43
Bone painMusculoskeletal and connective tissue disorders4/424/432/43
Hyperemia after injectionInjury, poisoning and procedural complications3/420/430/43

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Empegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastimTotal
<=18 years0000
Between 18 and 65 years424343128
>=65 years0000
Age, Continuous
Age, Continuous(years)Empegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastimTotal
Mean48.38 ± 11.0750.42 ± 9.1951.86 ± 9.6850.23 ± 10.03
Sex: Female, Male
Sex: Female, Male(Participants)Empegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastimTotal
Female424343128
Male0000
Region of Enrollment
Region of Enrollment(participants)Empegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastimTotal
Russian Federation424343128
Histologic type
Histologic type(participants)Empegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastimTotal
Infiltrative ductal27283388
Infiltrative lobular63211
Medullar0101
Squamous cell cancer0101
Infiltrative not specified45413
Low-grade differentiated carcinoma2316
Undifferentiated cancer3238
Disease stage
Disease stage(participants)Empegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastimTotal
IIA13121035
IIB57921
IIIA571022
IIIB1210830
IIIС2103
IV56617
History previous therapy of breast cancer
History previous therapy of breast cancer(participants)Empegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastimTotal
Adjuvant chemotherapy781025
Neoadjuvant chemotherapy1102
Radiotherapy84315
Hormone therapy67417
Surgery treatment28272277
Any treatment28292683
Duration of a disease
Duration of a disease(months)Empegfilgrastim 6 mgEmpegfilgrastim 7.5 mgFilgrastimTotal
Mean16.14 (1.0 to 144.0)11.62 (1.0 to 144.0)5.37 (1.0 to 51.0)11.0 (1.0 to 144.0)
08

Study locations

13 sites
  • Arkhangelsk District Clinical Oncology Dispensary
    Arkhangelsk, 163045, Russian Federation
  • Clinical Hospital at Chelyabinsk Railway Station
    Chelyabinsk, Russian Federation
  • State public health institution "Republican Clinical Oncology Dispensary" of the Ministry of Health of the Republic of Tatarstan
    Kazan, Russian Federation
  • Non-governmental healthcare institution "Central Clinical Hospital № 2 Semashko" JSC "Russian Railways"
    Moscow, Russian Federation
  • State Health Care Institution "Moscow City Oncology Hospital № 62" Moscow Health Department
    Moscow, Russian Federation
  • State public health institution "Nizhny Novgorod Regional Oncology Dispensary"
    Nizhny Novgorod, Russian Federation
  • Perm Region Oncology Dispensary
    Perm, 614066, Russian Federation
  • Pyatigorsk Oncology Center
    Pyatigorsk, 357502, Russian Federation
  • Federal State Educational Institution of Higher Professional Education "Mordovia State University N.P. Ogareva "
    Saransk, Russian Federation
  • N.N.Petrov Oncology Research Center
    St.Petersburg, 197758, Russian Federation
  • State public health institution "Regional Clinical Oncology Dispensary"
    Ulyanovsk, Russian Federation
  • Volgograd Regional Oncology Dispensary №3
    Volgograd, 404130, Russian Federation
  • State Health Care Institution "Volgograd Regional Clinical Oncology Dispensary № 1"
    Volgograd, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Jun 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2014
First posted
Apr 4, 2014
Start
Sep 2013
Primary completionActual
Jun 2014
CompletionActual
Oct 2014
Results first posted
Oct 24, 2016
Last update
Oct 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02104830
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Apr 4, 2014
Start date
Sep 2013
Primary completion
Jun 2014
Completion
Oct 2014
Results posted
Oct 24, 2016
Last update
Oct 24, 2016

Study contacts

Roman Ivanov, MD, PhD
study director · Biocad
Larisa Bolotina, MD, PhD
principal investigator · Federal State Institution "Moscow Research Oncological Institute P.A.Gertsena "of the Ministry of Health of the Russian Federation
Olga Brichkova, MD, PhD
principal investigator · State public health institution "Regional Oncology Dispensary №1
Olga Burdaeva, MD
principal investigator · State Budget Institution of Health Arkhangelsk region "Arkhangelsk Clinical Oncology Dispensary"
Byakhov Michael, MD, PhD
principal investigator · Non-governmental healthcare institution "Central Clinical Hospital № 2 Semashko" JSC "Russian Railways"
Vladimir Vladimirov, MD, PhD
principal investigator · State Budget Institution of Health Stavropol area "Piatigorsky Oncology Dispensary"
Rinat Galiulin, MD
principal investigator · State budget healthcare institution Omsk region "Clinical Oncology Dispensary"
Oleg Gladkov, MD, PhD
principal investigator · State Budget Institution of Health "Chelyabinsk Regional Clinical Oncology Dispensary"
Irina Davydenko, PhD
principal investigator · State Budget Institution of Health "Clinical Oncology Dispensary № 1" of the Ministry of Health of the Krasnodar area
Victoria Elkova, MD
principal investigator · State public health institution "Voronezh Regional Clinical Oncology Dispensary"
Igor Lifirenko, MD
principal investigator · State public health institution "Kursk Regional Oncology Dispensary"
Nadezhda Kovalenko, PhD
principal investigator · State Budget Institution of Health "Volgograd regional oncologic dispensary № 3"
Michael Kopp, MD, PhD
principal investigator · State Budget Institution of Health "Samara Regional Clinical Oncology Dispensary"
Bogdan Kotiv, MD, PhD
principal investigator · S. M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Natalia Levchenko, PhD
principal investigator · State Budget Institution of Health Stavropol area "Stavropol Regional Clinical Oncology Dispensary"
Marina Matrosova, MD
principal investigator · State public health institution "Nizhny Novgorod Regional Oncology Dispensary"
Guzel Mukhametshina, MD
principal investigator · State public health institution "Republican Clinical Oncology Dispensary" of the Ministry of Health of the Republic of Tatarstan
Sergei Panchenko, PhD
principal investigator · State public health institution "Regional Clinical Oncology Dispensary"
Alexander Pecheny, PhD
principal investigator · Regional State Health Care Institution "Orlovsky Oncology Dispensary"
Igor Pimenov, PhD
principal investigator · State Budget Institution health care "Tula Regional Oncology Dispensary"
Andrei Sinykov, PhD
principal investigator · State Health Care Institution of Tyumen Region "Regional Oncological Dispensary"
Pavel Skopin, PhD
principal investigator · Federal State Educational Institution of Higher Professional Education "Mordovia State University N.P. Ogareva "
Daniil Stroyakovsky
principal investigator · State Health Care Institution "Moscow City Oncology Hospital № 62" Moscow Health Department
Sergei Tyulyandin, MD, PhD
principal investigator · "Russian Oncological Scientific Center N.N.Blokhin" Russian Academy of Sciences
Dmitriy Udovica, MD
principal investigator · State Health Care Institution "Oncologic Dispensary № 2" Health Department of Krasnodar Area
Andrei Horinko, MD
principal investigator · State Health Care Institution "Perm Regional Oncology Dispensary"
Petr Krivorotko, MD
principal investigator · N.N. Petrov Oncology Research Center of the Ministry of Health of the Russian Federation
Yulia Shapovalova, PhD
principal investigator · Non-governmental healthcare institution "Chelyabinsk Road Clinical Hospital" JSC "Russian Railways"
Ludmila Sheveleva, MD
principal investigator · State Health Care Institution "Volgograd Regional Clinical Oncology Dispensary № 1"
Vadim Shirinkin, MD
principal investigator · State Health Care Institution "Orenburg Regional Clinical Oncology Dispensary"
Shekar Patil, MD
principal investigator · Bangalore Institute of Oncology
Prasad Narayanan, MD
principal investigator · Mazumdar Shaw Cancer Center and Narayana Hrudayalaya Multispecialty Hosptial
Nalini Kilara, MD
principal investigator · M.S.Ramaiah Memorial Hospital
Sergei Kulik, MD
principal investigator · Donetsk City Municipal Oncology Dispensary
Igor Sedakov, MD, PhD
principal investigator · Donetsk Regional oncology centers
Andrei Rusin, MD,PhD
principal investigator · Zakarpatskii Regional Clinical Oncology Dispensary
Yuri Vinnik, MD, PhD
principal investigator · Kharkiv Regional Clinical Oncology Center
Sergei Odarchenko, PhD
principal investigator · Vinnitskii Regional Oncology Dispensary

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Filgrastim

Start the discussion